Moderna (MRNA) Sliding Lower as EU Postpones Additional COVID Booster Deliveries, Pfizer (PFE) and Novavax (NVAX) on Watch

Shares of Moderna (NASDAQ: MRNA) are trading 2% lower Thursday morning as the company announced it had agreed to amend the delivery schedule of additional COVID-19 vaccine booster shots to the European Union.

The agreement, the first public announcement of its kind, is allowing participating EU Member States to postpone deliveries of Moderna's vaccine booster doses currently scheduled for Q2 2022 for later in 2022 or even early 2023.

It's too early to tell whether other countries will follow suit, and what effect such postponements may have on Moderna's bottom line, although negative financial implications can’t be ruled out. The company, on its end, continues "to expect advanced purchase agreements of approximately $21 billion for 2022 and continues to believe that COVID market dynamics will result in sales slightly higher in the second half of 2022 than in the first half."

The news comes as global COVID-19 case count continues to decline - on June 1st there were "only" 655K new cases reported globally. This compares to ~1.1M daily cases reported 2 month prior, and nearly 3.7M daily cases at the height of January 2022 COVID surge.

So far there's no noticeable chain reaction in other COVID-19 vaccine-dependent stocks - both Novavax (NASDAQ: NVAX) and Pfizer (NYSE: PFE) remain relatively quiet pre-market.

By Vlad Schepkov

You May Also Be Interested In

• EMA validates Pfizer and Valneva's Lyme disease vaccine application
• Top CPU stocks to buy as analysts say "renaissance thesis is playing out"
• This company "will win meaningful share of future AI workloads": BofA